Ptc Therapeutics (PTCT) Stock News

PTC Therapeutics (NASDAQ: PTCT) reported new Sephience™ (sepiapterin) data to be presented in 17 abstracts and presentations at the 2026 SSIEM Symposium in Helsinki, Aug. 25-28. The data include clinical trial and real‑world evidence showing blood phenylalanine (Phe) reduction, diet liberalization and sustained metabolic control in phenylketonuria (PKU) across patient subgroups, including classical and non‑BH4‑responsive PKU.

New AMPLIPHY analyses found a 100% greater Phe reduction in participants switching from sapropterin to Sephience. High‑baseline Phe patients (≥900 µmol/L) showed meaningful Phe reductions within 14 days. Real‑world data in adolescents indicate significant dietary liberalization with maintained metabolic control. Sephience remains associated with a consistent, favorable safety profile alongside labeled risks such as bleeding, hypophenylalaninemia, and specific drug interactions.

PTC Therapeutics (NASDAQ: PTCT) was selected as the winning bidder to acquire ST-920, a BLA-stage, one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics through a competitive bankruptcy auction. Terms include $111 million upfront and up to $100 million in contingent regulatory milestones.

ST-920’s rolling BLA for FDA accelerated approval is expected to be completed in Q4 2026, with potential U.S. commercial launch in 2027. The BLA is supported by Phase 1/2 STAAR data showing favorable 52-week renal function (positive eGFR slope), improvements in other Fabry manifestations, durable α-Gal A activity up to 4.5 years, and an encouraging safety profile without routine systemic immunosuppression. ST-920 has FDA RMAT, Orphan Drug and Fast Track designations. The deal, aligned with PTC’s rare disease strategy, is expected to close in late Q3 or early Q4 2026, subject to definitive documentation, bankruptcy court approval, antitrust review and other customary conditions.

PTC Therapeutics (NASDAQ: PTCT) reported Q2 2026 total revenue of $360.5 million, including $238.8 million in net product revenue and $71.1 million in Evrysdi royalties. Sephience™ generated $151.3 million with 1,647 patients on commercial therapy worldwide. The company recognized a $50 million milestone from Novartis for first dosing in the Phase 3 INVEST-HD study and posted GAAP net income of $83.5 million versus a prior-year loss. Cash, cash equivalents and marketable securities reached $2.23 billion, supported by a $550 million 0% senior convertible notes issue due 2031, alongside repurchase of most 1.5% notes due 2026.

PTC raised 2026 expected total revenue to $1.18–$1.28 billion, increasing product revenue guidance to $850–$950 million while maintaining GAAP and non-GAAP R&D and SG&A ranges. Pipeline updates included positive long-term votoplam data in Huntington’s disease, initiation of Phase 1 PTC612, expected Phase 2a start for PTC844 in Q3 2026, and naming PTC303 as a development candidate.

Hamilton Lane (Nasdaq: HLNE) announced that its Board of Directors elected Michael Schmertzler as a new independent director, effective July 22, 2026. His appointment brings the Board to five independent directors, serving alongside three executive directors.

Schmertzler has extensive investment, corporate finance and governance experience, including academic roles at Yale University and leadership positions at multiple companies such as PTC Therapeutics, Berryville Holdings, Dispel, SHY Therapeutics and AgNovos. Earlier in his career, he held senior roles at Credit Suisse First Boston Equity Partners and Morgan Stanley.

PTC Therapeutics (NASDAQ: PTCT) will host a webcast conference call to report its second quarter 2026 financial results and provide a business and outlook update on Thursday, July 30, 2026, at 4:30 p.m. ET. Investors can access the live webcast and a 30-day replay via the Investors "Events & Presentations" page on the PTC website. Phone participants are required to register in advance to receive dial-in details.

PTC Therapeutics (NASDAQ: PTCT) approved equity inducement awards for 18 new employees on June 11, 2026, under Nasdaq Listing Rule 5635(c)(4). These include non-statutory stock options for 10,050 shares and 11,870 RSUs, each RSU representing one common share upon vesting.

The stock options have a $74.71 exercise price, a 10-year term, and vest over four years: 25% after one year, then 6.25% quarterly. RSUs vest over four years in 25% annual installments, all subject to continued employment.

PTC Therapeutics (NASDAQ: PTCT) priced a private offering of $500 million 0% Convertible Senior Notes due 2031, with an option for an additional $50 million. The notes carry no cash interest, mature June 15, 2031, and are senior unsecured.

According to PTC Therapeutics, net proceeds of about $486.8 million will primarily refinance its 1.5% Convertible Senior Notes due 2026, including a concurrent cash repurchase of $222 million principal for a total cost of approximately $328.8 million. The initial conversion price is $107.48, a 40% premium to the June 15, 2026 close.

PTC Therapeutics (NASDAQ: PTCT) plans a private offering of $500 million Convertible Senior Notes due 2031, with an option for an additional $50 million, to qualified institutional buyers under Rule 144A.

According to PTC, net proceeds will primarily refinance its 1.5% Convertible Senior Notes due 2026 and fund approximately $50 million of common stock repurchases.

PTC Therapeutics (NASDAQ: PTCT) reported Q1 2026 total revenue of $273M, including $226M product revenue, and raised full‑year product revenue guidance to $750–$850M with total revenue guidance of $1.08–$1.18B. Sephience revenue was $124.6M (36% QoQ). Q1 GAAP R&D was $100.9M; GAAP SG&A was $86.2M. Net loss was $2.8M. Cash and marketable securities were $1.892B at March 31, 2026. Clinical updates include positive 24‑month PIVOT‑HD topline results for votoplam and plans to start an open‑label vatiquinone registration study in Q3 2026.